An Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With T1D
Clinical trial NCT05210530 · COMPLETED
Trial details
- NCT number
- NCT05210530
- Sponsor
- CRISPR Therapeutics AG
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-01-24
- Primary completion
- 2023-01-19
- Enrollment
- 7
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.